NTLA
Intellia Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$12.74
+0.47%Forward multiples
Based on analyst estimates
- P/E forward
- —
- P/E 2026E
- —
- P/E 2027E
- —
- P/E 2028E
- —
- P/S forward
- 33.67x
Trailing multiples
Trailing twelve months
- P/E TTM
- —
- PEG TTM
- —
- Price / book
- 2.45x
- Price / sales
- 30.00x
- Price / cash flow
- -3.85x
Enterprise value
- Enterprise value
- $1.4B
- EV / sales
- 23.88x
- EV / EBITDA
- -3.64x
- EV / EBIT
- -3.36x
- Market cap
- $1.8B
Trailing, forward and enterprise-value multiples for the requested listing · Data as of Jun 1, 2026